Microbiome Alterations as Predictive Biomarkers for Immunotherapy Response in Non-Small Cell Lung Cancer
DOI:
https://doi.org/10.70088/4z7rrk95Keywords:
microbiome, immunotherapy, non-small cell lung cancer, predictive biomarkers, personalized medicineAbstract
Non-small cell lung cancer (NSCLC) persist one of the leading effort of Crab-associate deathrate. Progress in immunotherapy have exhibit hope in meliorate survival rates, but patient answer remain extremely variable. Emerging grounds suggests that the human microbiome may playact a decisive role in tone the efficaciousness of immunotherapy. As prognosticative biomarkers for immunotherapy response in NSCLC patients, this inquiry investigates alteration. By use mellow-throughput sequencing and advanced bioinformatics, we identify specific microbic taxa and tract relate with responders and non-responders. Our determination cater a model for mix microbiome profiling into immunotherapy strategies, potentially enhancing treatment outcomes.References
J. Chau, M. Yadav, B. Liu, M. Furqan, Q. Dai, S. Shahi, et al., "Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer," BMC Cancer, vol. 21, no. 1, p. 808, 2021.
B. Liu, J. Chau, Q. Dai, C. Zhong, and J. Zhang, "Exploring gut microbiome in predicting the efficacy of immunotherapy in non-small cell lung cancer," Cancers, vol. 14, no. 21, p. 5401, 2022.
L. Huang, Y. Li, C. Zhang, A. Jiang, L. Zhu, W. Mou, et al., "Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors," npj Biofilms Microbiomes, vol. 11, no. 1, p. 180, 2025.
A. B. Malczewski, S. Navarro, J. I. Coward, and N. Ketheesan, "Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy," J. Immunother. Cancer, vol. 8, no. 2, p. e001383, 2020.
M. Zhang, J. Liu, and Q. Xia, "Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target," Exp. Hematol. Oncol., vol. 12, no. 1, p. 84, 2023.
B. Oh, F. Boyle, N. Pavlakis, S. Clarke, T. Eade, G. Hruby, et al., "The gut microbiome and cancer immunotherapy: can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy?," Cancers, vol. 13, no. 19, p. 4824, 2021.
M. A. W. Khan, G. Ologun, R. Arora, J. L. McQuade, and J. A. Wargo, "Gut microbiome modulates response to cancer immunotherapy," Dig. Dis. Sci., vol. 65, no. 3, pp. 885-896, 2020.
C. Huang, M. Li, B. Liu, H. Zhu, Q. Dai, X. Fan, et al., "Relating gut microbiome and its modulating factors to immunotherapy in solid tumors: a systematic review," Front. Oncol., vol. 11, p. 642110, 2021.
S. Ren, L. Feng, H. Liu, Y. Mao, and Z. Yu, "Gut microbiome affects the response to immunotherapy in non-small cell lung cancer," Thorac. Cancer, vol. 15, no. 14, pp. 1149-1163, 2024.
B. Routy, E. Le Chatelier, L. Derosa, C. P. Duong, M. T. Alou, R. Daillère, et al., "Gut microbiome influences efficacy of PD-1--based immunotherapy against epithelial tumors," Science, vol. 359, no. 6371, pp. 91-97, 2018.
G. Roviello, L. F. Iannone, M. Bersanelli, E. Mini, and M. Catalano, "The gut microbiome and efficacy of cancer immunotherapy," Pharmacol. Ther., vol. 231, p. 107973, 2022.
A. L. Stancu, "Gut microbiome and the response to immunotherapy in cancer," Discoveries, vol. 6, no. 3, p. e84, 2018.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Robert Fischer (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
